You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The deal expands Illumina's cloud-based data analysis portfolio and gives its customers access to tools to boost assay and operational efficiency.
UK-based Abcam has acquired Oregon-based life science research tool provider Marker Gene Technologies, the latest in a string of asset purchases.
The company expects that Blueprint's informatics capabilities in particular will improve variant interpretation and reporting across all its genetic test offerings.
Abcam said that acquisition will help it build out a discovery engine for developing novel edited cell lines and support its knockout validation initiative.
Psomagen is buying bankrupt microbiome testing firm uBiome's assets, Stat News reports.
The UK firm has purchased the assets for Enigma Diagnostics and anticipates it will soon receive clearance to market its first test for TB in China.
The technology, called PrecisMed, is designed to detect, measure, and assess over 200 medications in a patient's bloodstream from a finger stick.
Illumina officials discussed several issues with investors, including the new Qiagen partnership, while at ASHG the firm introduced reagent kit upgrades.
The UK Competition and Markets Authority said blocking the deal could prevent a "substantial lessening of competition" in the NGS market.
The combined company will use RNA-based tools to enhance drug development by identifying the right patients for oncology drugs and potentially improving drug response rates.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.